Rubicon Research Ltd
Rubicon Research Ltd Live Price Chart
Performance
| Previous Close | ₹ 1804.4 |
| High | ₹ 1855 |
| Volume | 319228 |
| 52W Range | ₹ 570.75 - ₹ 1899 |
| Open | ₹ 1812 |
| Low | ₹ 1780.4 |
| Market Cap | ₹ 25123.29 Cr |
Rubicon Research Ltd Technicals
| 20 Day | ₹ 1,709.434 |
| 50 Day | ₹ 1,551.217 |
| 100 Day | ₹ 1,350.153 |
| 200 Day | ₹ 1,033.810 |
| 20 Day | ₹ 1,698.793 |
| 50 Day | ₹ 1,545.622 |
| 100 Day | ₹ 1,291.477 |
| 200 Day | ₹ 1,000.897 |
Rubicon Research Ltd Fundamentals
| ROCE | 17.415 |
| P/E Ratio | 127.820 |
| P/B Ratio | 22.230 |
| Industry P/E | 22.230 |
| Debt to Equity | 51.431 |
| ROE | 13.904 |
| EPS | 14.220 |
| Dividend Yield | 0.080 |
| Book Value | 81.756 |
| Face Value | 1.000 |
Rubicon Research Ltd Financials
| Particulars | Y202603 | Y202503 | Y202403 | Y202303 | Y202203 |
|---|---|---|---|---|---|
| Total Revenue | 1316.914 | 1093.524 | 656.9433 | 418.999 | 417.4134 |
| Total Expenses | 1064.135 | 870.244 | 622.8684 | 430.048 | 400.4908 |
| Profit After Tax | 188.165 | 167.537 | 24.3499 | -16.888 | 16.6832 |
Rubicon Research Ltd Shareholding Pattern
| Promoter Holdings | 59.757 % |
| FIIs | 7.517 % |
| DIIs | 2.201 % |
| MutualFund | 7.228 % |
| Retail | 3.458 % |
| Others - | 19.839 % |
About Rubicon Research Ltd
Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from Rubicon Consultants Private Limited' to Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002. The Company's status got converted from a Private Company to a Public Company, the name was changed from Rubicon Research Private Limited' to Rubicon Research Limited'. A fresh Certificate of Incorporation dated July 23, 2024 was issued by the Central Processing Centre, Manesar, Haryana. Rubicon Research is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products. The Company is driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets, particularly, the United States. It has obtained its GMP manufacturing facilities at Ambernath and Satara in Maharashtra. The Company commenced manufacturing of certain special drugs in Ambernath Manufacturing Facility in 2011. In 2016, the Company acquired majority stake by ECP III Pte Ltd. Further, it acquired majority stake by General Atlantic Singapore RR Pte. Ltd., from ECP III Pte. Ltd. in 2019. In 2021, the Company acquired the business of Meditab Specialities Limite ...
Similar Stocks
| Ambalal Sarabhai Enterprises Ltd Pharmaceuticals | ₹ 45.62 +1.61 (+3.66%) |
| Amrutanjan Health Care Ltd Pharmaceuticals | ₹ 509.35 -4.9 (-0.95%) |
| Astrazeneca Pharma India Ltd Pharmaceuticals | ₹ 6,951.50 -155 (-2.18%) |
| Bliss GVS Pharma Ltd Pharmaceuticals | ₹ 616.75 +28.65 (+4.87%) |
| Abbott India Ltd Pharmaceuticals | ₹ 25,850.00 -325 (-1.24%) |
| Cipla Ltd Pharmaceuticals | ₹ 1,409.20 -14.3 (-1%) |
FAQs on Rubicon Research Ltd
1. Can I buy Rubicon Research Ltd from PL Capital? ›
2. Does Rubicon Research Ltd pay dividends? ›
3. What is the current share price of Rubicon Research Ltd ? ›
4. What is the 52-week high and low of Rubicon Research Ltd ? ›
Start SIP in Rubicon Research Ltd
Invest systematically in stocks with the
PL Capital app
Are you a new user? Open your account
